On January 28, 2021, Cuthbertson, Alan; Boehnke, Niels published a patent.HPLC of Formula: 282734-37-6 The title of the patent was Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer. And the patent contained the following:
The invention is related to the preparation of compounds I [n = 1-3; R1-4 = OH or Q; Q = a tissue-targeting moiety selected from the group consisting of poly- and oligopeptides, proteins, DNA and RNA fragments, aptamers polyclonal or monoclonal antibodies, and a mixture of proteins or fragments or constructs of protein] their stereoisomers, hydrates, solvates and salts, and targeted radiopharmaceuticals, pharmaceutical compositions and combinations comprising them and their use for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients. The experimental process involved the reaction of (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(5-bromopyridin-2-yl)propanoic acid(cas: 282734-37-6).HPLC of Formula: 282734-37-6
The Article related to peptide chelator conjugate preparation antitumor prostate cancer, preparation peptide chelator thorium 227 her2 fap psma conjugate, prostate specific membrane antigen carboxy hopo thorium 227 conjugate, targeted radiopharmaceutical prostate cancer and other aspects.HPLC of Formula: 282734-37-6